Pharmacy and Pharmaceutical Sciences Commons^™

Method For Designing Compounds And Compositions Useful For Targeting High Stoichiometric Complexes To Treat Conditions, Including Treatment Of Viruses, Bacteria, And Cancers Having Acquired Drug Resistance, Peixuan Guo, Dan Shu

Pharmaceutical Sciences Faculty Patents

A method is described for the identification o f multi-subunit biocomplex drug targets. The method includes identifying a target that performs a biological function, wherein the target comprises one or more subunits, wherein a minimum number of the one or more subunits is inactivated to inhibit the biological function. The method includes selecting a drug that binds specifically to each subunit of the one or more subunits with a target probability. The method describes a relationship between inhibition efficiency of the drug and total number of the one or more subunits using a binomial distribution, wherein the inhibition efficiency comprises …

Proteasome Inhibitors, Kyung Bo Kim, Venod Kasam, Wooin Lee, Dong-Eun Kim, Zachary Miller, Chang-Guo Zhan, Do-Min Lee

Pharmaceutical Sciences Faculty Patents

To see this patent's abstract, please download it.

Methods To Impair Hematologic Cancer Progenitor Cells And Compounds Related Thereto, Craig T. Jordan

Pharmaceutical Sciences Faculty Patents

Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leuke mia (CML) and chronic lymphoid leukemia (CLL). Interleu kin-3 receptor alpha chain (IL-3Ra or CD123) is strongly expressed on progenitor hematologic cancer cells, but is vir tually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hemato logic cancer (e.g., leukemia and lymphomic) cells by selec tively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malig nant lymphoproliferative …

Bis-Quaternary Ammonium Cyclophane Compounds That Interact With Neuronal Nicotinic Acetylcholine Receptors, Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, Davis D. Allen, Zhenfa Zheng, Paul Lockman

Pharmaceutical Sciences Faculty Patents

Provided are bis-quaternary ammonium cyclophane compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.

Bis-Pyridino Containing Compounds For The Use In The Treatment Of Cns Pathologies, Peter A. Crooks, Linda P. Dwoskin, Joshua Ayers, Vladimir Grinevich, Sangeetha Sumithran

Pharmaceutical Sciences Faculty Patents

N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter.

Removing Aluminum From Solution Using Chelating Compounds And Immobilized Tethered Chelators, Robert A. Yokel, Wesley R. Harris, Christopher D. Spilling, Chang-Guo Zhan

Pharmaceutical Sciences Faculty Patents

Methods are described for removing aluminum from a solution using novel di- and tripodal compounds as chelators.

Methods And Pharmaceutical Compositions For Decorporation Of Radioactive Compounds, Michael Jay, Russell J. Mumper

Pharmaceutical Sciences Faculty Patents

A composition for removing a radioactive element or compound such as systemic transuranic compounds, from mammals comprises a pharmaceutical carrier and a decorporation agent comprising ester and amide derivatives of DTPA. A method of treating a mammal to remove systemic compounds utilizing the DTPA derivatives is also disclosed.

Chelating Compounds And Immobilized Tethered Chelators, Robert A. Yokel, Wesley R. Harris, Christopher D. Spilling, Chang-Guo Zhan

Pharmaceutical Sciences Faculty Patents

Novel di- and tripodal compounds useful as chelators, intermediates for their production and a method for treating an aqueous solution to remove trivalent metal ions are presented.

Compounds Of Use In The Treatment Of Epilepsy, Seizure, And Electroconvulsive Disorders, Peter A. Crooks, Aimee K. Bence, David Robert Worthern

Pharmaceutical Sciences Faculty Patents

The present invention provides pharmaceutical preparations and the uses thereof for preventing and/or treating seizures and other electroconvulsive disorders by administering a pharmaceutically effective amount of a therapeutic compound . . .

To view the rest of this abstract, please download this patent.

Bridged Nicotine Compounds For Use In The Treatment Of Cns Pathologies, Peter A. Crooks, Linda P. Dwoskin, Rui Xu, Vladimir P. Grinevich

Pharmaceutical Sciences Faculty Patents

Pharmaceutical compounds comprising bridged nicotine analogs of N-octylnicotinium iodide (NONI) having selective antagonist properties at α3β2-containing nicotinic receptor subtypes, and compositions containing these compounds. The compounds and compositions are used to treat central nervous system pathologies.

Use Of Lobeline Compounds In The Treatment Of Central Nervous System Diseases And Pathologies, Peter A. Crooks, Linda P. Dwoskin

Pharmaceutical Sciences Faculty Patents

Lobeline and nicotine evoke [³H]overflow from rat striatal slices preloaded with [³H]dopamine ([³H]DA). The lobeline-evoked overflow is calcium-independent and not antagonized by mecamylamine, suggesting a mechanism of action other than the stimulation of nicotinic receptors. Whereas nicotine stimulates nicotinic receptors, lobeline inhibits [³H]DA uptake into synaptic vesicles and striatal synaptosomes. The results suggest that different mechanisms are responsible for the increase in striatal DA release evoked by lobeline and nicotine. [³H]-Dihydrotetrabenazine [³H]DTBZ), used routinely to probe a high-affinity binding site-on the vesicular monoamine transporter (VMAT2) binds to vesicle …

Lobeline Compounds As A Treatment For Psychostimulant Abuse And Withdrawal, And For Eating Disorders, Peter A. Crooks, Linda P. Dwoskin

Pharmaceutical Sciences Faculty Patents

Methods are disclosed that suggest the use of lobeline and analogs thereof in treating individuals for drug dependence and withdrawal and for eating disorders.

Triazoline Anticonvulsant Compounds And Compositions, Pankaja K. Kadaba

Pharmaceutical Sciences Faculty Patents

Anticonvulsant compositions comprise as the active ingredient a compound . . .

To see the remainder of this abstract, please download this patent.

Triazoline Anticonvulsant Drugs, Pankaja K. Kadaba

Pharmaceutical Sciences Faculty Patents

Anticonvulsant compositions comprise as the active ingredient a compound . . .

To see the remainder of this abstract, please download this patent.